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Abstract
Adipose derived mesenchymal stem cells (ASCs) transplantation is a novel
immunomodulatory therapeutic tool to ameliorate the symptom of inflammatory
bowel disease (IBD). The objective of this study was to investigate the therapeutic
effects of combined sufasalazine and ASCs therapy in a rat model of IBD. After
induction of colitis in rats, ASCs were cultured and intraperitoneally injected
(3 × 106cells/kg) into the rats on Days 1 and 5 after inducing colitis, in conjunction
with daily oral administration of low dose of sulfasalazine (30mg/kg). The
regenerative effects of combination of ASCs and sulfasalazine on ulcerative colitis
were assessed by measuring body weight, colonic weight/length ratio, disease activity
index, macroscopic scores, histopathological examinations, cytokine, and inflamma-
tion markers profiles. In addition, western blot analysis was used to assess the levels
of nuclear factor‐kappa B (NF‐κB) and apoptosis related proteins in colitis tissues.
Simultaneous treatment with ASCs and sulfasalazine was associated with significant
amelioration of disease activity index, macroscopic and microscopic colitis scores, as
well as inhibition of the proinflammatory cytokines in trinitrobenzene sulfonic
acid (TNBS)‐induced colitis. Moreover, combined ASCs and sulfasalazine therapy
effectively inhibited the NF‐κB signaling pathway, reduced the expression of Bax and
prevented the loss of Bcl‐2 proteins in colon tissue of the rats with TNBS‐induced
colitis. Furthermore, combined treatment with ASCs and sulfasalazine shifted
inflammatory M1 to anti‐inflammatory M2 macrophages by decreasing the levels of
MCP1, CXCL9 and increasing IL‐10, Arg‐1 levels. In conclusion, combination of ASCs
with conventional IBD therapy is potentially a much more powerful strategy to slow
the progression of colitis via reducing inflammatory and apoptotic markers than
either therapy alone.
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1 | INTRODUCTION
Inflammatory bowel diseases (IBDs) arechronic, relapsing, inflamma-
tory disorders of the gastrointestinal tract which include ulcerative
colitis (UC) and Crohn’s disease. These two manifestations of IBD are
a global health concern considering their growing incidence that
affects millions of people worldwide (M’koma, 2013). To date, the
etiology and pathogenesis of chronic IBD are still poorly understood.
However, it seems that dysregulation of mucosal immune reaction
against intestinal microflora and excessive mucosal damage caused
by specific intestinal antigens contributes to the pathogenesis of
chronic IBD (Wallace, Zheng, Kanazawa, & Shih, 2014). Various
compounds and approaches, such as 5‐aminosalicylates (5‐ASA),
sulfasalazine, corticosteroids, immunosuppressive agents or selective
biological inhibitors of inflammatory pathways, including tumor
necrosis factor ⍺ (TNF‐⍺), have been traditionally used for medical
treatments of IBD. However, the limited effectiveness of long‐term
treatment, undesirable side effects, inconvenient dosing regimen of
the conventional drugs and the frequent failure to induce and
maintain remission have limited their extensive application (Stavely
et al., 2015).
Stem cell‐based therapy, as a promising alternative strategy,
has recently attracted considerable attention for the treatment of
IBD (Duran & Hommes, 2016). Mesenchymal stem cells (MSCs),
which are multipotent cells that can be easily isolated from
various tissues and are capable of differentiating into cells of
mesodermal lineage, such as bone, cartilage, muscle, and fat, are
considered as an attractive candidate for cell therapy. The
capacity of MSCs to differentiate into diverse cell lineages
demonstrates that these cells have the potential to promote
healing of the damaged tissues or organs (Robinson et al., 2014;
Shirian et al., 2016). In addition, MSCs exert immunomodulatory
and anti‐inflammatory effects by decreasing the production of
inflammatory cytokine and the number of inflammatory cells, such
as DCs, natural killer cells (NKs), T and B cells (Kyurkchievet al.,
2014; Zhang et al., 2009). Therefore, hundreds of clinical trials are
being carried out using MSCs for treatment of several immune
mediated conditions, including Graft vs Host Disease (GVHD),
aplastic anemia, Crohn's disease, rheumatoid arthritis, and multi-
ple sclerosis (Zhao, Ren, & Han, 2016).
Combining cell therapy and low doses of traditional medications,
such as transplantation of MSC combined with administration of
sulfasalazine, can provide improved therapeutic outcome with fewer
side effects compared with long‐term administration of high doses of
conventional medications.
In the present study, MSCs, derived from adipose tissue, have
been used due to the ease of accessibility and their higher
suppression effects on inflammatory cells than other sources of
MSCs, such as bone marrow, amnion, and umbilical cord (Ivanova‐
Todorova et al., 2009).
Sulfasalazine is selected as the reference drug in most of the
studies conducted on colitis. Moderate to high doses of sulfasalazine
(100–500mg/kg) are usually applied as the positive control. The aims
of the present study were to investigate the therapeutic effects of
combination of low dose of sulfasalazine (30mg/kg) and adipose
derived mesenchymal stem cells (ASCs) in a trinitrobenzene sulfonic
acid (TNBS)‐induced IBD rat model as well as the capacity of this
combination therapy to restore immune tolerance and inhibit the
inflammatory responses in vivo.
Our hypothesis was that ASCs transplantation together with
administration of low dose of sulfasalazine would result in an
increase in regenerative responses of each of the treatments alone.
The results of the present study indicated that the combination
therapy synergistically enhances colon regeneration, reduces active
inflammation, and improves overall colon function compared with
either of the treatments alone.
2 | MATERIALS AND METHODS
2.1 | Isolation and expansion of adipose‐MSCs
The human ASCs were isolated from lipoaspirates obtained from
human adipose tissue of healthy adult donors. Tissues were
washed with PBS before being digested with collagenase type I
(0.1%) in PBS. An equal volume of Dulbecco’s modified Eagle’s
medium (DMEM; Gibco‐Invitrogen, Carlsbad, CA) containing 10%
fetal bovine serum (FBS; Gibco‐Invitrogen) was added to the
collagenase type I solution to stop collagenase activity and the
mixture was centrifuged at 1,000g for 5 min to obtain a cell pellet
which was then resuspended in 1 ml of expansion medium
(DMEM/F12 supplemented with 100 U/ml penicillin–streptomycin,
1% glutaMAX (Gibco‐Invitrogen), and 20% FBS (MSC‐qualified;
Gibco). The isolated cells were seeded into the culture flasks
containing expansion medium at a density of 100,000 cells/cm2.
The culture medium was replaced every 24 hr for a period of
3 days to get rid of nonadherent contaminating cells.
2.2 | Flow cytometric analysis
The cell surface marker profile of ASCs was investigated by flow
cytometry analysis. Approximately, 5 × 105 cells at passage 2 to 6
were incubated with specific PE‐ or FITC‐conjugated mouse
anribodies against human CD11b, CD34, CD44, CD90, CD105
(eBioScience, San Diego, CA), and subjected to flow cytometric
analysis using a Beckman Colter flow cytometer and FACScan
program (eBioScience).
2.3 | Animals
The experimental protocols were approved by the Animal Care
and Use Committees of the Tehran University of Medical Sciences
(TUMS). All animal procedures were approved by the ethical
committee of the TUMS. Ten‐week‐old male Wistar rats (180–
220 g) were obtained from the animal house of the School of
Medicine, TUMS (Tehran, Iran). Three rats were housed per cage in
a temperature‐controlled room (20–24°C) with a 12‐hr light/dark
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cycle. All the rats had access to standard laboratory chow and
water ad libitum.
2.4 | TNBS‐induced colitis model
To induce colitis, TNBS (Sigma‐Aldrich, Deisenhofen, Germany) was
dissolved in ethanol 50% to reach a concentration of 40mg/kg and
was intrarectally administered 8 cm proximal to the anus (total
volume of 300 μl) using a lubricated silicone catheter (Rashidian
et al., 2016). For TNBS administration, rats were anesthetized with
diethyl ether. The animals were maintained in a head side down
position for 1 min to prevent any solution leakage.
2.5 | Experiment design
The animals were randomly assigned to seven groups, each consisting
of six rats and the following treatments were performed for each
group:
1. Control group (50% ethanol + normal saline).
2. TNBS group (TNBS + normal saline).
3. Sulfasalazine group (TNBS + sulfasalazine 30mg/kg/day).
4. ASCs group (TNBS + ASCs).
5. ASCs + sulfasalazine 30 group (TNBS + ASCs + sulfasalazine
30 mg/kg/day).
The animals were orally administered with normal saline and
sulfasalazine. Moreover, ASCs were intraperitoneally injected on
Days 1 and 5 postcolitis induction (cells were suspended in
phosphate buffered saline [PBS], 1 × 106/0.3 ml/rat).
2.6 | The disease activity index (DAI)
The severity of the induced colitis was assessed using the DAI. To
this end, the animals were weighed and the stool consistency as well
as the presence and degree of occult or gross rectal bleeding were
recorded on a daily bases. The DAI was determined, as previously
described (El‐Salhy & Umezawa, 2016), by rating the percentage
of the body weight loss (0, no body weight loss; 1, 1–5%; 2, 6–10%; 3,
11–15%; and 4, >15%), stool consistency (0, normal; 2, loose; 4,
diarrhea) and the degree of rectal bleeding (0, normal; 2, occult
bleeding; and 4, gross bleeding). The DAI was assessed by averaging
these three separate scores.
2.7 | Colon macroscopic damage and area of
colonic lesions
Severity of the induced colitis was evaluated by an independent
observer blind to the identity of the treatments according to a scale
ranging from 0 to 4 as follows: 0, no macroscopic changes; a, mucosal
erythema only; b, mild mucosal edema, slight bleeding or small erosions;
c, moderate edema, bleeding ulcers or erosions; and d, severe ulceration,
erosions, edema, and tissue necrosis (Millar et al., 1996).
2.8 | Histological evaluation and
immunohistochemistry (IHC)
The colon samples were embedded in paraffin and cut into 5 μm
sections which were then deparaffinized, cleared, and rehydrated in a
graded ethanol series. The sections were stained with hematoxylin
and eosin and scored (Ren, Yuan, Zhang, Wei, & Wang, 2015)
considering the following parameters: (a) inflammation (0, none; 1,
slight; 2, moderate; 3, severe); (b) extent of injury (0, none; 1, mucosa;
2, mucosa and submucosa; 3, transmural); (c) crypt damage (0, none;
1, basal 1/3 damage; 2, basal 2/3 damage; 3, only surface epithelium
lost; 4, entire crypt and epithelium lost), and (d) percent involvement
(×1: 0–25%, ×2: 26–50%, ×3: 51–75%, ×4: 76–100%). The total score
was the sum of all the above parameters. For evaluation of
myeloperoxidase (MPO) using IHC, paraffin‐embedded sections
(4 μm) of the colon tissue were deparaffinized in xylene, washed in
a graded ethanol series, and rehydrated in PBS. Antigen retrieval was
performed in citrate buffer (pH 6.0) for 15min at 3°C using a
steamer. The nonspecific binding sites were blocked by incubating
the tissue sections in a 3% bovine serum albumin solution for 1 hr at
37°C followed by incubation of the samples with the primary
antibody against MPO (rabbit polyclonal to MPO; 1:100; Abcam,
Cambridge, MA) at 4°C, overnight. The tissue sections were then
incubated with goat–anti‐rabbit IgG (HRP‐conjugate; 1:100; Abcam)
for 1 hr at 37°C. No washing step was performed between incubation
with the primary and secondary antibodies. Finally, the slides were
stained with diaminobenzidine (Boster Biological Technology Ltd.,
Wuhan, China) at room temperature for 10min and the staining
process was stopped with distilled water. The prepared tissue
sections were then counterstained with hematoxylin for 5min,
dehydrated in alcohol and xylene, and covered with neutral balsam.
2.9 | Western blot analysis
The colon tissue samples were homogenized in standard radio-
immunoprecipitation assay buffer. The supernatant was removed
after centrifugation at 12,500g for 20min at 4°C. Total protein
concentration was determined using a NanoDrop 2000C (Thermo
Fisher Scientific, Waltham, MA). Equal amounts (100 μg) of proteins
were separated from each sample using 10% sodium dodecyl sulfate
polyacrylamide gel electrophoresis and transferred to poly vinylidene
fluoride membranes.
The membranes were blocked with 5% nonfat dry milk and 0.1%
Tween‐20 in Tris‐buffered saline for 1 hr at room temperature, followed
by incubation with rabbit anti‐NF‐κB p65 (1:500 dilution), Bcl‐2 (1:5,000
dilution), Bax (1:5,000 dilution), and anti‐β‐actin (1:500 dilution)
antibodies (Abcam) at 4°C overnight. After being washed with Tris‐
buffered saline Tween‐20, the membranes were incubated with a
secondary goat–anti‐rabbit IgG (HRP‐conjugate; 1:10,000; Abcam)
antibody at room temperature for 1 hr. A western blot detection
system (West–Zol® Plus, iNtRON Biotechnology, Daejun, Korea) was
used to detect the target proteins on the membranes, according to the
instruction of the manufacturer, before being exposed to the X‐ray films
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(Bio-Rad, Hercules, CA). Density of the protein bands was quantified
using Quantity One® 1‐D analysis software (Bio‐Rad).
2.10 | Enzyme‐linked immunosorbent assay
The expression levels of TNF‐α, IL‐6, and IL‐1β proteins in the colon
tissue lysates were determined using the ELISA kits as described by
the manufacturer (R&D Systems, Minneapolis, MN).
2.11 | Gene expression analysis using real‐time
quantitative
Total RNA was extracted using the RNeasy Mini Kit (QIAGEN AB,
Sollentuna, Sweden). cDNA was synthesized using the SuperScript
TMII enzyme (18064‐014; Invitrogen) and quantitative real‐time
polymerase chain reaction (qRT‐PCR) was performed using Fast
SYBR Green Master Mix (Applied Biosystems, Foster City, CA)
applying the primers detailed in Table 1. The thermal cycling
conditions consisted of an initial denaturation step at 95°C for
5min, 35 cycles of 94°C for 15 s, 55°C for 15 s, and 72°C for 15 s,
followed by a final extension step at 72°C for 10min. GAPDH was
chosen as a housekeeping gene and used as an internal comparator in
parallel with the control sample.
2.12 | Statistical analysis
All the values are expressed as mean ± standard deviation. The data
were analyzed by GraphPad Prism, version 5.04 (GraphPad Software
Inc., San Diego, CA). Differences between the groups were evaluated
using an analysis of variance, followed by the Tukey’s post‐hoc test.
p < 0.05 was considered statistically significant.
3 | RESULTS
3.1 | Cell characteristics and phenotypic and
functional validation of ASCs
MSC‐specific markers, namely CD44, CD90, and D105, were strongly
expressed in the ASCs whereas the expression levels of CD34
(hematopoietic progenitors) and CD11b (leukocyte common antigen)
were not detectable (Figure 1a).
The fibroblastic‐like ASCs grew in monolayer culture, adhered to
the plastic surface and proliferated. To determine the ASCs
differentiation capacity, cells were cultured in specialized culture
media to induce osteogenic and adipogenic differentiation. Success of
osteogenic and adipogenic differentiation was confirmed using
Alizarin Red S and Oil Red O, respectively (Figure 1b).
3.2 | Combination treatment improves
macroscopic tissue damage in TNBS‐induced
colitis in rats
To investigate the potential of coadministration of ASCs and low dose
of sulfasalazine to attenuate colon inflammation, its efficacy was
analyzed in the TNBS‐induced colitis in rats as an experimental model of
IBD. After intrarectal instillation of TNBS, the rats suffered a significant
weight loss (Table 2) accompanied by severe bloody diarrhea,
macroscopic damage score (as damage degree) and elevated colon
weight to length ratio (an indicator of the ongoing colon inflammation)
compared with the control rats. However, the macroscopic score and
weight/length ratio of the colon were effectively improved in the ASCs‐
treated groups compared with that in the sulfasalazine and TNBS
groups (Table 2). Nevertheless, a significant reduction in these
TABLE 1 Primers applied for real‐time PCR
Genes Primer sequence Amplicon size (bp)
IL‐10 Forward: 5´‐GGGAAGCAACTGAAACTTCG‐3´ 330
Reverse: 5´‐GCTTTCGAGACTGGAAGTGG ‐3´
MCP‐1 Forward: 5´‐TGCTGTCTCAGCCAGATGCAGTTA‐3´ 356
Reverse: 5´‐AGAAGTGCTTGAGGTGGTTGTGGA‐3´
CXCL9 Forward: 5´‐GACTCCAGCACGGTGACTTA‐3´ 136
Reverse: 5´‐ATGCAGGAGCATCGCTGATT‐3´
ARG1 Forward: 5´‐TTGGAACGAAACGGGAAGGT‐3´ 113
Reverse: 5´‐TGTTCGGTTTGCTGTGATGC‐3´
FoxP3 Forward: 5´‐AGAGTGCTAGAGCCAAGTGC‐3´ 286
Reverse: 5´‐GGCCACTGTTAGGGTATGGG‐3´
Sphingosine kinase Forward: 5´‐CTCTTCCGAGCAGAAAGGGAA‐3´ 290
Reverse: 5´‐AGTGTGCAGCTGCTTATCGG‐3´
Sphingosine‐1‐phosphate lyase Forward: 5´‐CTGCACCAAATACGAGCCCT‐3´ 188
Reverse: 5´‐TGGCTTTGGTAAGCTGCTGT‐3´
GAPDH Forward: 5´ GTCGGTGTGAACGGATTTG‐3´ 181
Reverse: 5´‐TCCCATTCTCAGCCTTGAC‐3´
Note. PCR: polymerase chain reaction.
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parameters was observed in ASCs + sulfasalazine group compared to all
the other groups (Table 2). Interestingly, we observed a similar pattern
of DAI improvement and recovery in the ASCs + sulfasalazine treated
group compared with all the other groups (Figure 2B).
3.3 | Histological improvement in response
to combination treatment
Histopathological assessment of the TNBS‐instilled rats included
focal necrosis of the mucosa, erosion, loss of goblet cells, and
submucosal edema which were characterized by high levels of
inflammatory cell infiltration. Histopathological scores of the TNBS‐
induced colitis were dramatically decreased in the rats treated with
the combination of ASCs + sulfasalazine compared to the experi-
mental groups treated with either sulfasalazine or ASCs. Collectively,
these results suggest that ASCs and sulfasalazine provide a strong
protection against TNBS‐induced colonic damages (Figure 3).
TNBS instillation promoted a massive neutrophil infiltration, as
revealed by the higher intracolon MPO (a biomarker for activated
neutrophils) levels observed in the colitis‐induced rats compared
with the healthy control group. Similarly to the colitis scores, the
expression level of MPO in the ASCs + sulfasalazine‐treated group
was significantly lower than that detected in the experimental groups
treated with either ASCs, sulfasalazine or TNBS (Figure 4).
F IGURE 1 Morphology, characterization and differentiation capacity of human adipose mesenchymal stem cells (ASCs). (a) Morphology of the
cultured whale mesenchymal stem cells (magnifications: ×100) and flow cytometry analyses of ASCs cell surface markers. Positive markers (CD44,
CD90, and CD105) were expressed whereas negative markers (CD34 and CD11b) were not [Color figure can be viewed at wileyonlinelibrary.com]
TABLE 2 Effect of combination treatment on macroscopic parameters of colitis induced by TNBS in rats
Groups % Change of body weight (g) Colonic weight to length ratio (mg/cm) Macroscopic damage (score 0–4)
Control 7.5 ± 1.6 93.7 ± 6 0
MSCs 0.8 ± 0.5** 170.63 ± 7.5** 1.4 ± 0.8*
TNBS −20.2 ± 2.9### 296.4 ± 12.4### 3.92 ± 0.43###
Sulfasalazine −10.6 ± 2.7 208.4 ± 11.5* 2.9 ± 0.65
MSC + sulfasalazine 3.32 ± 1.3***&$$ 121.2 ± 4.6***&$ 0.7 ± 0.25**&$
Note. MSCs: mesenchymal stem cells; TNBS: trinitrobenzene sulfonic acid.
**p < 0.01, *p < 0.05, ###p < 0.001 versus control group, ***p < 0.001 versus TNBS group, $$$p < 0.001, versus sulfasalazine group, &&p < 0.01,
&&&p < >0.001, versus MSCs group, $$p < 0.01, $p < 0.05, &p < 0.001.
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3.4 | ASCs and inflammatory cytokine levels
To determine the immune response modulation induced by the
combination ASCs and low dose of sulfasalazine, the expression
levels of cytokines were analyzed in the colon tissues of colitis‐
induced rats. The expression levels of the cytokines, namely
TNF‐α, IL‐1, IL‐6, IL‐17, IL‐10, and TGF‐β, were measured using
enzyme‐linked immunosorbent assays. Although treatment with
ASCs alone resulted in a significant decrease in the levels of these
proinflammatory cytokines, the combination of ASCs and sulfasa-
lazine reduced the expression levels of these cytokines to a
greater extent (Figure 5). Conversely, the expression levels of
IL‐10 and TGF‐β (as anti‐inflammatory cytokines) were increased
in the colon with administration of ASCs as well as combination
therapy (Figure 5).
3.5 | Combination treatment shifted macrophage
functional phenotype in the colitis‐induced colon
To investigate the effects of combination therapy on macrophage
M1/M2 polarization in colonic tissues, the gene expression levels of
M1 and M2 markers were assessed using qRT‐PCR. The gene
expression level of M1 marker, MCP‐1, was significantly down-
regulated in all the treatment groups. However, this downregulation
was grater in the ASCs + sulfasalazine group compared to that in the
experimental groups treated with either sulfasalazine or ASCs
(Figure 6). Conversely, the expression levels of M2 markers, such
as arginase‐1 (Arg‐1), TGF‐β1, and IL‐10, were significantly
upregulated in ASCs‐treated group compared with that in the groups
treated with either TNBS or sulfasalazine. Moreover, treatment with
ASCs + sulfasalazine further increased the expression levels of M2
markers (Figure 6c,d).
3.6 | Combination treatment increased
Treg‐specific gene expression
Further analyses were performed on the expression levels of the
transcription factor, FoxP3, as a marker of regulatory T (Treg) cells
using qRT‐PCR. The expression level of FoxP3 was upregulated in the
ASCs groups, treated either alone or in combination with sulfasalazine.
However, treatment with ASCs + sulfasalazine significantly upregulated
the expression level of FoxP3 compared to any other treatment. These
results indicated that ASCs treatment increased T reg cell differentia-
tion via upregulation of Foxp3 gene expression (Figure 7).
3.7 | Combination treatment altered the protein
expression of nuclear factor‐kappa B (NF‐κB),
p65, Bax and Bcl‐2 in colonic tissue
Results of the western blot assay indicated that the protein
expression of NF‐kB p65 in TNBS group was markedly increased
compared with the normal group (p < 0.01). Nevertheless, both ASCs
and ASCs plus sulfasalazine treatment significantly diminished the
induced upregulation of NF‐κB p65 protein expression (Figure 8).
The expression level of proapoptotic protein, Bax, was significantly
increased, whereas that of the antiapoptotic protein, Bcl‐2 was
F IGURE 2 (A) Images of the colon tissue 9 days after colitis induction: (a) control; (b) ASCs; (c) TNBS; (d) Sulfasalazine 30;
(e) ASCs + sulfasalazine 30. (B) Effects of combination treatment on DAI in the experimental colitis rat model. #p < 0.05, ##p < 0.01, ###p < 0.001
versus control group, *p < 0.05, **p < 0.01, **p < 0.001 versus TNBS group, $p < 0.05, $$p < 0.01, $$$p < 0.001 versus sulfasalazine group, and
&p < 0.05, &&p < 0.01, &&&p < 0.001 versus MSCs group. ASCs: adipose derived mesenchymal stem cells; DAI: disease activity index; MSC:
mesenchymal stem cells; TNBS: trinitrobenzene sulfonic acid [Color figure can be viewed at wileyonlinelibrary.com]
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significantly decreased in the colitis rats. These changes were also
reversed by ASCs transplantation alone or together with sulfasalazine
treatment (Figure 8).
3.8 | Combination treatment modulated SphK/S1P
and related signaling pathways
To examine whether coadministration of ASCs and low dose of
sulfasalazine ameliorates colonic damage in the colitis‐induced rat
model through regulation of the SphK/S1P axis, the expression level
of SphK1 was measure using qRT‐PCR. The mRNA level of SphK1 in
TNBS group was significantly upregulated compared to the normal
group (p < 0.01). However, downregulated level of SphK1 was
observed after ASCs transplantation alone. Downregulation of
SphK1 mRNA level was greater in the experimental group treated
with the combination of ASCs + sulfasalazine compared to the
TNBS group (Figure 9a). Furthermore, measuring the gene expres-
sion level of SPL using qRT‐PCR revealed that the SPL expression
level was considerably downregulated in the TNBS group. However,
it was significantly upregulated in the experimental groups treated
with either ASCs alone or in combination with sulfasalazine
(Figure 9b).
4 | DISCUSSION
In the early stages of IBD, the conventional treatment which are
typically applied by clinicians’ include ASA, namely sulfasalazine and
mesalazine. Sulfasalazine is the most commonly prescribed anti‐
inflammatory agents in IBD (van Staa, Card, Logan, & Leufkens,
2005). However, it has been proven that sulfasalazine causes side
F IGURE 3 Histology of colonic sections. Representative of H&E stained colon sections. Magnifications: ×400. (a) Control. (b) ASCs. (c) TNBS.
(d) Sulfasalazine 30. (e) ASCs + sulfasalazine 30. (f) Effect of ASCs transplantation on the histological score. #p < 0.05, ##p < 0.01, ###p < 0.001
versus control group, *p < 0.05, **p < 0.01, ***p < 0.001 versus TNBS group, $p < 0.05, $$p < 0.01, $$$p < 0.001 versus sulfasalazine group and
&p < 0.05, &&p < 0.01, &&&p < 0.001 versus MSCs group. ASCs: adipose derived mesenchymal stem cells; H & E: hematoxylin & eosin;
MSC: mesenchymal stem cells; TNBS: trinitrobenzene sulfonic acid [Color figure can be viewed at wileyonlinelibrary.com]
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effects, including nausea, headache, and anorexia, as well as
hemolysis, many of which are dose‐dependent and can be avoided
by lowering the dosage of sulfasalazine (Peppercorn, 1984).
Therefore, to reduce toxicity and adverse effects of conventional
therapeutic approaches, it seems necessary to apply combination
therapy by administering lower dosages of each drug for treatment
of the disease (Sultan, Berkowitz, & Khan, 2017). In addition,
combination therapy has other advantages, including increased
effectiveness of treatment and greater clinical responses, as well as
cost effectiveness and minimized metabolic side effects (Hanauer,
2017; Sultan et al., 2017).
The objective of this study was to evaluate the effectiveness of
combination therapy with intraperitoneal injection of ASCs and
sulfasalazine in a rat model of TNBS‐induced colitis. TNBS‐induced
colitis in rat is characterized by transmural intestinal inflammation
and dysregulation of innate and adaptive immune responses that
present characteristics similar to those of human IBD (Liu, Wang, &
Hu, 2017).
MSCs are a heterogeneous subset of stromal cells with self‐
renewal ability and multipotent differentiation potential that can
be isolated from fat, bone marrow, umbilical cord, amniotic fluid,
placenta, and other tissues. MSCs have been demonstrated to
exert potent anti‐inflammatory and immunomodulating effects
on almost all the cells of the innate and adaptive immune systems
via direct cell–cell contact and secretion of soluble paracrine
factors, such as cytokines and chemokines (Kyurkchiev et al.,
2014). Previous studies have indicated that MSCs induce their
therapeutic and regenerative effects on animal models of colitis
by regulating and reducing the infiltration of activated immune
cells at the colon site (Zhang et al., 2009). In this context, the
F IGURE 4 Immunohistochemical staining against MPO in colonic sections of different treatment groups (×400). (a) Control. (b) ASCs.
(c) TNBS. (d) Sulfasalazine 30. (e) ASC + sulfasalazine 30. (f) The expression levels of MPO‐positive cells in the colon tissue. Data are
expressed as mean ± SD (n = 6). #p < 0.05, ##p < 0.01, ###p < 0.001 versus control group, *p < 0.05, **p < 0.01, ***p < 0.001 versus TNBS
group, $p < 0.05, $$p < 0.01, $$$p < 0.001 versus sulfasalazine group. &p < 0.05, &&p < 0.01, &&&p < 0.001 versus ASCs group. ASCs: adipose
derived mesenchymal stem cells; MPO: myeloperoxidase; MSC: mesenchymal stem cells; TNBS: trinitrobenzene sulfonic acid;
SD: standard deviation [Color figure can be viewed at wileyonlinelibrary.com]
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advantages of ASCs over MSCs derived from other sources
include easy isolation and high yield, as well as high therapeutic
and immune‐modulatory potentials (Melief, Zwaginga, Fibbe, &
Roelofs, 2013).
In the present study, all the macroscopic and microscopic
signs of inflammatory activities were significantly improved in
the ASCs + sulfasalazine group compared to the other treatment
groups.
MPO is a heme enzyme that is most abundantly secreted in
neutrophils and stored in their azurophilic granules. MPO is used as
an indirect measure of intensity of tissue inflammation; it’s high level
reflects an increased neutrophil infiltration as well as inflammation.
F IGURE 5 The effects of combination treatment on the cytokines profile. The protein levels of anti‐inflammatory TGF‐β1 (a) and IL‐10
(b) as well as proinflammatory TNF‐α (c), IL‐1β (d), IL‐6 (e), and IL‐17 (f) in colon extracts were measured by ELISA. #p < 0.05, ##p < 0.01,
###p < 0.001 versus control group, *p < 0.05, **p < 0.01, ***p < 0.001 versus TNBS group, $p < 0.05, $$p < 0.01, $$$p < 0.001 versus sulfasalazine
group and &p < 0.05, &&p < 0.01, &&&p < 0.001 versus ASCs group. MSCs adipose derived mesenchymal stem cells; ELISA: enzyme‐linked
immunosorbent assay; MSC: mesenchymal stem cells; TNBS: trinitrobenzene sulfonic acid [Color figure can be viewed at
wileyonlinelibrary.com]
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The experimental groups treated with ASCs, especially ASCs +
sulfasalazine group, presented a significantly reduced levels of
MPO expression in the colonic tissue.
Production of proinflammatory cytokines, such as TNF‐α, IL‐1,
and IL‐6 were significantly inhibited and the protein expression
levels of anti‐inflammatory cytokines, including IL‐10 and TGF‐β
were upregulated in the colon samples of ASCs‐sulfasalazine
groups.
Moreover, the expression level of Foxp3, a master regulator of
Treg cell development and function, was upregulated in the colon
tissues of ASCs‐treated groups compared with the TNBS group,
which suggests that ASCs can be effectively applied in IBD treatment
and they induce their effects through increasing the amounts of Treg
cells. A similar result has been found when bone marrow mesench-
ymal stem cells were transplanted in a murine model of colitis (Chen
et al., 2013).
Coadministration of ASCs and sulfasalazine downregulated the
expression levels of inflammatory M1 macrophage markers, CXCL9
and MCP‐1, whereas upregulated that of the anti‐inflammatory M2
macrophage markers, Arg‐1 and IL‐10. These results are consistent
with the findings of the studies conducted on animal model of IBD
that have reported a M1 to M2 macrophage phenotype switching
after treatment with extracts and exosomes from MSCs (Mao et al.,
2017; Song et al., 2017).
It has been demonstrated that ASCs exert protective effects against
intestinal inflammation in a murine model of colitis by decreasing the
number of inflammatory T cells as well as inflammatory cytokines and
increasing the number of regulatory T cells as well as anti‐inflammatory
cytokines (Gonzalez‐Rey, Gonzalez, Rico, Buscher, & Delgado, 2009).
Akiyama et al. (2012) have reported that bone marrow‐derived MSCs
ameliorated dextran sulfate sodium (DSS)‐driven colitis via activation of
Fas death pathway in inflammatory T cells.
Several studies have proven that MSCs have the ability to inhibit
cytotoxicity of NK cells and T cell proliferation via production of
prostaglandin E2 (Németh et al., 2009), repression of differentiation
of circulating T follicular helper cells by production of indoleamine
2,3‐dioxygenease (François, Romieu‐Mourez, Li, & Galipeau, 2012),
stimulation of immunomodulatory cytokines synthesis, such as
TGFβ1, IL‐10, HGF, IL‐1 receptors antagonist and TNF‐stimulated
gene 6 proteins (TSG‐6), and induction of macrophage polarization
toward anti‐inflammatory M2 phenotype (Zheng, Ge, Qiu, Shu, &
Xu, 2015).
F IGURE 6 M1 to M2 macrophage polarization. Expression levels of the macrophage phenotype‐associated genes were evaluated by
qRT‐PCR. (a) MCP‐1 and (b) CXCL9 (M1 marker), and (c) IL‐10 and (d) Arg‐1 (M2 marker). #p < 0.05, ##p < 0.01, ###p < 0.001 versus control
group, *p < 0.05, **p < 0.01, ***p < 0.001 versus TNBS group, $p < 0.05, $$p < 0.01, $$$p < 0.001 versus sulfasalazine group and &p < 0.05,
&&p < 0.01, &&&p < 0.001 versus MSCs group. ASC: adipose derived mesenchymal stem cells; MSC: mesenchymal stem cells; qRT‐PCR:
quantitative real‐time polymerase chain reaction; TNBS: trinitrobenzene sulfonic acid [Color figure can be viewed at wileyonlinelibrary.com]
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A recent clinical trial has reported that using placenta‐derived
mesenchymal‐like adherent cells is a safe and efficient approach to
treat IBD (Melmed et al., 2015). Another study has reported that
autologous adipose‐derived MSCs were able to completely heal
fistula in 82% (27/33) of their patients, 8 weeks following final MSCs
transplantation (Lee et al., 2013).
In recent years, investigators have shown that pretreatment of
MSCs with cytokines, such as interleukin‐25 (IL‐25), interferon‐γ
(IFN‐γ), and TNF‐⍺, as well as granulocyte colony stimulating factor
(G‐CSF) enhance their therapeutic effects on colitis via an anti‐
inflammatory mechanism (Cheng et al., 2017).
The results of the present study demonstrated that the
combination cell therapy with mesenchymal stem cells and low dose
of sulfasalazine could considerably be a more effective colitis therapy
than either therapy alone.
Duijvestein et al. (2011) have found that MSCs phenotype,
survival, differentiation, immunosuppressive capacity and in vitro
function are not affected by therapeutic doses of commonly used
drugs for the treatment of IBD. This suggests that coadministration
of MSCs and IBD drugs can be effectively used for colitis treatment.
One of the main findings of the present study was the remarkable
downregulation of sphingosine kinase (SphK) mRNA expression level
in the rat model of colitis after ASCs transplantation. SphK is a key
enzyme in synthesis of sphingosine‐1‐phosphate (S1P) which tightly
regulates S1P levels in tissues and plasma. Another key regulator of
sphingolipid metabolism is sphingosine‐1‐phosphate lyase (SPL) that
catabolizes the irreversible degradation of S1P into ethanolamine
phosphate and hexadecenal (Nielsen, Li, Johansson‐Lindbom, &
Coskun, 2017).
S1P is a bioactive sphingolipid metabolite that is synthesized from
sphingosine and ATP by SphKs and exerts diverse biological and
immunologic effects. S1P, by activating STAT and NF‐κB signaling
pathways, mediates inflammatory responses and leukocyte trafficking
to the sites of inflammation within the gastrointestinal tract (Wollny
et al., 2017). Several studies have reported high levels of S1P expression
accompanied with dysregulated of SphKs pattern in inflammation sites,
such as inflamed mouse and human intestine (Crespo et al., 2017;
Karuppuchamy et al., 2017; Suh & Saba, 2015). On the other hand, SPL
is highly expressed in normal intestine but downregulated in the colon
of IBD and colorectal cancer patients as well as the murine
experimental colitis (Crespo et al., 2017; Nielsen et al., 2017). In IBD,
activation of STAT‐ and NF‐κB‐mediated pathways markedly increases
the risk of malignant cell growth and tumor formation (Wollny et al.,
2017). Therefore, targeting SphK/S1P axis may represent an important
therapeutic approach for controlling inflammation in IBD and prevent-
ing colon carcinogenesis (Wollny et al., 2017).
A recent study has found that ASCs secretome can inhibit
inflammatory responses of microglia via modulation of sphingosine
kinase/S1P signaling (Marfia et al., 2016). Moreover, findings of the
present study indicated that ASCs treatment reverses upregulation
of SphK and downregulation of SPL in the colonic tissues of rat with
TNBS‐induced colitis. These results are consistent with those of the
previous studies indicating that attenuation of S1P signaling via SphK
inhibitors significantly abrogates colitic damage and reduces the
expression levels of inflammatory molecules, IL‐6 and COX‐2.
Moreover, it was observed that colitis severity and inflammation
were enhanced by deletion of SPL after dextran sulfate sodium
treatment (Degagné et al., 2014; Xi et al., 2016).
To the best our knowledge, this is the first report demonstrating
that ASCs are able to ameliorate progression of colitis by modulation
of S1P signaling pathway through suppressing SphK and increasing
SPL expression.
The results of this study indicated that combined administration
of ASCs and low dose of sulfasalazine induces synergistic anti‐
inflammatory and regenerative effects on colitis.
In the present study, coadministration of ASCs and sulfasalazine
significantly downregulated the expression level of NF‐κB in the
colon tissue of TNBS‐induced colitis rat model.
NF‐κB, as a central transcription factor and mediator of
inflammatory responses, regulates expression of many genes and
plays crucial roles in immune and inflammatory reactions. Several
clinical and preclinical studies have confirmed that NF‐κB is
activated in the IBD patients and the animal model of colitis
and contributes to pathogenesis of IBD (Neurath, Becker, &
Barbulescu, 1998; Rashidian et al., 2016; Wang, Fan, & Cao, 2016).
Downregulation of the NF‐κB activity emerges as a very attractive
target for therapeutic intervention in intestinal inflammation
(Neurath et al., 1998).
Increasing evidence suggests that apoptosis is one of the main
mechanisms involved in colitis (Giriş et al., 2008, Gu et al., 2017, Liu,
F IGURE 7 The expression levels of Treg marker Foxp3 in colon
tissues. #p < 0.05, ##p < 0.01, ###p < 0.001 versus control group,
*p < 0.05, **p < 0.01, ***p < 0.001 versus TNBS group, $p < 0.05,
$$p < 0.01, $$$p < 0.001 versus sulfasalazine group and &p < 0.05,
&&p < 0.01, &&&p < 0.001 versus MSCs group. ASCs: adipose derived
mesenchymal stem cells; mRNA: messenger RNA;
MSC: mesenchymal stem cells; TNBS: trinitrobenzene sulfonic acid
[Color figure can be viewed at wileyonlinelibrary.com]
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F IGURE 8 The protein expression levels of NF‐κB, p65, Bcl‐2, and Bax in colon extracts. (a) Representative western blot showing protein
levels of NF‐κB p65, Bcl‐2, Bax, and β‐actin protein. Changes in the expression level of NF‐κB p65 (b), Bax (c), Bcl‐2 (d) proteins after treatment.
Data are expressed as mean ± SD (n = 6). ##p < 0.01 versus control group, *p < 0.05, **p < 0.01 versus TNBS group and $p < 0.05 versus
sulfasalazine group. MSC: mesenchymal stem cells; TNBS: trinitrobenzene sulfonic acid; SD: standard deviation [Color figure can be viewed at
wileyonlinelibrary.com]
F IGURE 9 Effect of combination treatment on the SphK/S1P signaling pathway‐related genes. mRNA expression levels of SphK1 (a) and SPL
(b) genes. #p < 0.05, ##p < 0.01, versus control group. *p < 0.05, **p < 0.01, versus TNBS group. $p < 0.05, $$p < 0.01, versus sulfasalazine group.
&p < 0.05, versus MSCs group. mRNA: messenger RNA; S1P: sphingosine‐1‐phosphate; SphK1: sphingosine kinase; SPL: sphingosine‐1‐
phosphate lyase [Color figure can be viewed at wileyonlinelibrary.com]
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Shi, Wang, Zhu, & Zhao, 2016). In this experiment, coadministration
of ASCs and sulfasalazine significantly reversed the downregulation
of antiapoptotic protein, Bcl‐2, and upregulation of apoptotic protein,
Bax after induction of colitis.
Our results suggest that the therapeutic and regenerative effects
of coadministration of ASCs and sulfasalazine may be partially
explained by downregulation of proinflammatory cytokines levels,
inhibition of the NF‐κB pathway activation, and moderation of
apoptosis occurrence.
The obtained data suggest that combination therapy with MSCs
and sulfasalazine (as a reference drug in IBD treatment) may offer
potent synergistic therapeutic, anti‐inflammatory and colon recon-
structive effects and can be used to improve colitis symptoms in IBD
patients.
5 | CONCLUSION
In conclusion, we have demonstrated that combination treatment
with ASCs along with low dose of sufasalazine exhibited significant
anti‐inflammatory and regenerative effects than either monotherapy
in the mouse model of colon inflammation. The current study
suggests that concurrent administration of ASCs and sulfasalazine
may be useful to improve clinical outcome of IBD treatment. These
results may be used to develop new cell‐based therapeutic
approaches for colitis.
It is important to note that the implications of the present
findings are not exclusively limited to colitis, as the observed synergy
effect could also potentiate the individual effect of each component
in other inflammatory conditions that are targeted by this treatment
(such as rheumatoid arthritis); therefore, it subsequently plays a
crucial role in the field of inflammatory diseases.
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